Search Results - "Leeper, Brittaney A"

EGFR Inhibition Enhances the Cellular Uptake and Antitumor-Activity of the HER3 Antibody-Drug Conjugate HER3-DXd by Haikala, Heidi M, Lopez, Timothy, Köhler, Jens, Eser, Pinar O, Xu, Man, Zeng, Qing, Teceno, Tyler J, Ngo, Kenneth, Zhao, Yutong, Ivanova, Elena V, Bertram, Arrien A, Leeper, Brittaney A, Chambers, Emily S, Adeni, Anika E, Taus, Luke J, Kuraguchi, Mari, Kirschmeier, Paul T, Yu, Channing, Shiose, Yoshinobu, Kamai, Yasuki, Qiu, Yang, Paweletz, Cloud P, Gokhale, Prafulla C, Jänne, Pasi A

“…Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) are the standard-of-care treatment for -mutant non-small cell lung cancers (NSCLC)…”
Get full text

An allosteric inhibitor against the therapy-resistant mutant forms of EGFR in non-small cell lung cancer by To, Ciric, Beyett, Tyler S, Jang, Jaebong, Feng, William W, Bahcall, Magda, Haikala, Heidi M, Shin, Bo H, Heppner, David E, Rana, Jaimin K, Leeper, Brittaney A, Soroko, Kara M, Poitras, Michael J, Gokhale, Prafulla C, Kobayashi, Yoshihisa, Wahid, Kamal, Kurppa, Kari J, Gero, Thomas W, Cameron, Michael D, Ogino, Atsuko, Mushajiang, Mierzhati, Xu, Chunxiao, Zhang, Yanxi, Scott, David A, Eck, Michael J, Gray, Nathanael S, Jänne, Pasi A

“…Epidermal growth factor receptor (EGFR) therapy using small-molecule tyrosine kinase inhibitors (TKIs) is initially efficacious in patients with EGFR-mutant…”
Get full text

Targeting TRIP13 in favorable histology Wilms tumor with nuclear export inhibitors synergizes with doxorubicin by Mittal, Karuna, Cooper, Garrett W., Lee, Benjamin P., Su, Yongdong, Skinner, Katie T., Shim, Jenny, Jonus, Hunter C., Kim, Won Jun, Doshi, Mihir, Almanza, Diego, Kynnap, Bryan D., Christie, Amanda L., Yang, Xiaoping, Cowley, Glenn S., Leeper, Brittaney A., Morton, Christopher L., Dwivedi, Bhakti, Lawrence, Taylor, Rupji, Manali, Keskula, Paula, Meyer, Stephanie, Clinton, Catherine M., Bhasin, Manoj, Crompton, Brian D., Tseng, Yuen-Yi, Boehm, Jesse S., Ligon, Keith L., Root, David E., Murphy, Andrew J., Weinstock, David M., Gokhale, Prafulla C., Spangle, Jennifer M., Rivera, Miguel N., Mullen, Elizabeth A., Stegmaier, Kimberly, Goldsmith, Kelly C., Hahn, William C., Hong, Andrew L.

“…Wilms tumor (WT) is the most common renal malignancy of childhood. Despite improvements in the overall survival, relapse occurs in ~15% of patients with…”
Get full text

Merkel Cell Carcinoma Sensitivity to EZH2 Inhibition Is Mediated by SIX1 Derepression by Gartin, Ashley K., Frost, Thomas C., Cushman, Camille H., Leeper, Brittaney A., Gokhale, Prafulla C., DeCaprio, James A.

“…Polycomb repressive complex 2 has a critical role in the maintenance of bivalent promoters and is often perturbed in cancer, including neuroendocrine tumors…”
Get full text

The BRD4-NUT Fusion Alone Drives Malignant Transformation of NUT Carcinoma by Durall, R Taylor, Huang, Julianna, Wojenski, Luke, Huang, Yeying, Gokhale, Prafulla C, Leeper, Brittaney A, Nash, Joshua O, Ballester, Pedro L, Davidson, Scott, Shlien, Adam, Sotirakis, Emmanuel, Bertaux, Fabien, Dubus, Vincent, Luo, Jia, Wu, Catherine J, Keskin, Derin B, Eagen, Kyle P, Shapiro, Geoffrey I, French, Christopher A

“…NUT carcinoma (NC) is an aggressive squamous carcinoma defined by the BRD4-NUT fusion oncoprotein. Routinely effective systemic treatments are unavailable for…”
Get full text

Hyper-Dependence on NHEJ Enables Synergy between DNA-PK Inhibitors and Low-Dose Doxorubicin in Leiomyosarcoma by Marino-Enriquez, Adrian, Novotny, Jan Philipp, Gulhan, Doga C, Klooster, Isabella, Tran, Antuan V, Kasbo, Macy, Lundberg, Meijun Z, Ou, Wen-Bin, Tao, Derrick L, Pilco-Janeta, Daniel F, Mao, Victor Y, Zenke, Frank T, Leeper, Brittaney A, Gokhale, Prafulla C, Cowley, Glenn S, Baker, Laurence H, Ballman, Karla V, Root, David E, Albers, Joachim, Park, Peter J, George, Suzanne, Fletcher, Jonathan A

“…Leiomyosarcoma (LMS) is an aggressive sarcoma for which standard chemotherapies achieve response rates under 30%. There are no effective targeted therapies…”
Get full text

EZH2 Cooperates with BRD4-NUT to Drive NUT Carcinoma Growth by Silencing Key Tumor Suppressor Genes by Huang, Yeying, Durall, R Taylor, Luong, Nhi M, Hertzler, Hans J, Huang, Julianna, Gokhale, Prafulla C, Leeper, Brittaney A, Persky, Nicole S, Root, David E, Anekal, Praju V, Montero Llopis, Paula D L M, David, Clement N, Kutok, Jeffery L, Raimondi, Alejandra, Saluja, Karan, Luo, Jia, Zahnow, Cynthia A, Adane, Biniam, Stegmaier, Kimberly, Hawkins, Catherine E, Ponne, Christopher, Le, Quan, Shapiro, Geoffrey I, Lemieux, Madeleine E, Eagen, Kyle P, French, Christopher A

“…NUT carcinoma is an aggressive carcinoma driven by the BRD4-NUT fusion oncoprotein, which activates chromatin to promote expression of progrowth genes. BET…”
Get full text

Allosteric inhibition of drug resistant forms of EGFR L858R mutant NSCLC by To, Ciric, Beyett, Tyler S., Jang, Jaebong, Feng, William W., Bahcall, Magda, Haikala, Heidi M., Shin, Bo H., Heppner, David E., Rana, Jaimin K., Leeper, Brittaney A., Soroko, Kara M., Poitras, Michael J., Gokhale, Prafulla C., Kobayashi, Yoshihisa, Wahid, Kamal, Kurppa, Kari J., Gero, Thomas W., Cameron, Michael D., Ogino, Atsuko, Mushajiang, Mierzhati, Xu, Chunxiao, Zhang, Yanxi, Scott, David A., Eck, Michael J., Gray, Nathanael S., Jänne, Pasi A.

“…Although treatment with small molecule epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) is initially efficacious for patients with…”
Get full text